2H23 Pharma/Biotech Outlook (Part. 1)
We are now at the end of the tumultuous first half of the year. We still have a week remaining as of today, but as investors, we are always forward-looking.…
$XBI is no longer a good way to have exposure / to hedge biotech – single stock picking / shorting is more important than ever
We are all aware of how bad $xbi (biotech ETF) has been over the past year. $XBI is flat over the past three years, down -30% over the past year,…